Aligos Therapeutics (NASDAQ: ALGS) is scheduled to reveal its financial results for the third quarter on Wednesday 6th November 2024. This disclosure will take place after market close, providing investors with significant information regarding the company's performance in the last three months period.
In accordance with the predictions of financial analysts on Wall Street, the organization is on track to report an expected per share of $2.16 loss for the quarter. Furthermore, the firm is projected to disclose a total revenue of $0.33 million for this quarter.
Wall Street analysts have revealed their projections for the company's yearly performance, with a total revenue of $2.68 million. Furthermore, they expect the business to achieve loss of $6.71 per share during the fiscal year.
The company's earnings report for the corresponding quarter of the previous year showcased a per-share loss of $0.41. This figure was a result of the company's total revenue, which reached an impressive $2.15 million million during that specific period.
Aligos Therapeutics (ALGS) closed Friday's regular trading session at $9.55, reflecting a 2.35 percent fall. The stock fluctuated between $9.33 and $10.30 during the day, with a volume of 60.70 thousand shares.
